Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for bladder cancer: experimental drug joins standard combo

NCT ID NCT07232602

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding an experimental drug (MK-3120) to the standard treatment (enfortumab vedotin plus pembrolizumab) is safe and effective for people with advanced bladder cancer that has spread. About 55 participants will receive the new combination. Researchers will monitor side effects and measure how many patients' tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MK-3120 (an investigational drug) given with enfortumab vedotin and pembrolizumab
What this could lead to
If it works, this could lead to a more effective first-line treatment for advanced bladder cancer, potentially shrinking tumors in more patients.
What could go wrong
This is an early phase 1/2 trial with only 55 participants, so results may not apply to everyone. Adding a new drug to standard therapy also raises unknown safety risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Asan Medical Center ( Site 5901)

    RECRUITING

    Seoul, 05505, South Korea

  • CHU de Bordeaux Hop St ANDRE ( Site 5607)

    RECRUITING

    Bordeaux, Gironde, 33075, France

  • Cleveland Clinic Taussig Cancer ( Site 5036)

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Erasmus MC ( Site 5303)

    RECRUITING

    Rotterdam, South Holland, 3015 GD, Netherlands

  • FALP ( Site 5151)

    RECRUITING

    Santiago, Region M. de Santiago, 7500921, Chile

  • Hospital Clinico San Carlos ( Site 5765)

    RECRUITING

    Madrid, 28040, Spain

  • Hospital Universitari Vall de Hebron ( Site 5767)

    RECRUITING

    Barcelona, 08035, Spain

  • Huntsman Cancer Institute ( Site 5041)

    RECRUITING

    Salt Lake City, Utah, 84112-5550, United States

  • Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 5302)

    RECRUITING

    Amsterdam, North Holland, 1066 CX, Netherlands

  • Rabin Medical Center ( Site 5504)

    RECRUITING

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus ( Site 5501)

    RECRUITING

    Haifa, 3109601, Israel

  • Samsung Medical Center ( Site 5902)

    RECRUITING

    Seoul, 06351, South Korea

  • Severance Hospital, Yonsei University Health System ( Site 5903)

    RECRUITING

    Seoul, 03722, South Korea

  • St Bartholomew s Hospital ( Site 5206)

    RECRUITING

    London, London, City of, EC1A 7BE, United Kingdom

  • UCSF Medical Center at Mission Bay ( Site 5044)

    RECRUITING

    San Francisco, California, 94158, United States

  • University of Chicago Medical Center ( Site 5037)

    RECRUITING

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.